WASHINGTON, DC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Engage experts and patients and conduct research and education to support development of therapies for patients in need.
1.In support of its goal to conduct research and education, the organization engaged experts and stakeholders in the field of cell- cell-based therapy, including researchers from academic, research...
1.In support of its goal to conduct research and education, the organization engaged experts and stakeholders in the field of cell- cell-based therapy, including researchers from academic, research, and industry organizations, and those representing patients, to assess the current state of the field; identify barriers to the development, translation, and manufacturing of safe and effective therapies; identify strategies and policies for addressing such barriers; and develop white papers outlining actions needed to advance the field. 2.In support of its goal to conduct research and education, the organization developed reports, white papers, briefs, and other com- communications materials and hosted virtual events featuring
nationally recognized experts and scientists, as well as patients, to support charitable and educational purposes of the organization. 3.In support of its goal to provide educational resources to...
nationally recognized experts and scientists, as well as patients, to support charitable and educational purposes of the organization. 3.In support of its goal to provide educational resources to support patients, the organization made publicly available, guides to support patient decision-making related to cell-based therapies. 4.In support of its goal to expand the evidence base associated with cell-based therapies for patients in need, the organization analyzed clinical trials exploring the use of regenerative medicine and cell therapies for patients in need.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | N/A | $175,000 | -1.0% |
| Expenses | $4,567 | $167,310 | -1.0% |
| Net Income | N/A | $7,690 | N/A |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JANET MARCHIBRODA | PRESIDENTSECRETARY | N/A |
Officer
Director
|
$0 | $0 | $0 |
| MARIA MILLAN | DIRECTOR | N/A |
Director
|
$0 | $0 | $0 |
| KRISHNENDU ROY | DIRECTOR | N/A |
Director
|
$0 | $0 | $0 |
| FRED SANFILIPPO | DIRECTORCHAIRMAN | N/A |
Officer
Director
|
$0 | $0 | $0 |
| MICHELE REISNER | TREASURER | N/A |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | No data | $4,567 | $817 | No data |
| 2022 | $175,000 | $167,310 | $10,175 | $7,690 |
Compare ALLIANCE FOR CELL THERAPY FOUNDATION with other nonprofits in District of Columbia and across the country.